Skip Navigation
ChemIDplus A TOXNET DATABASE LiteBrowseAdvanced

Substance Name: Pirenzepine hydrochloride [USAN:JAN]
RN: 29868-97-1
UNII: 10YM403FLS
InChIKey: FFNMBRCFFADNAO-UHFFFAOYSA-N

Note

  • An antimuscarinic agent that inhibits gastric secretion at lower doses than are required to affect gastrointestinal motility, salivary, central nervous system, cardiovascular, ocular, and urinary function. It promotes the healing of duodenal ulcers and due to its cytoprotective action is beneficial in the prevention of duodenal ulcer recurrence. It also potentiates the effect of other antiulcer agents such as CIMETIDINE and RANITIDINE. It is generally well tolerated by patients.

Molecular Formula

  • C19-H21-N5-O2.2Cl-H

Molecular Weight

  • 424.3297
 

Classification Codes

  • Anti-Ulcerative
  • Drug / Therapeutic Agent
  • Reproductive Effect
* denotes mobile formatted website

Links to Resources


Search for this InChIKey on the Web

Names and Synonyms

Name of Substance

  • Pirenzepine dihydrochloride
  • Pirenzepine hydrochloride [USAN:JAN]

Synonyms

  • 5,11-Dihydro-11-((4-methyl-1-piperazinyl)acetyl)-6H-pyrido(2,3-b)(1,4)benzodiazepin-6-one dihydrochloride
  • 6,11-Dihydro-11-((4-methyl-1-piperazinyl)acetyl)-5H-pyrido(2,3-b)(1,4)benzodiazepin-6-on dihydrochlorid
  • 6H-Pyrido(2,3-b)(1,4)benzodiazepin-6-one, 5,11-dihydro-11-((4-methyl-1-piperazinyl)acetyl)-, dihydrochloride
  • Bisvanil
  • EINECS 249-907-5
  • Gastrozepin
  • Leblon
  • LS 519 cl2
  • LS 519 dihydrochloride
  • LS 519Cl2
  • Maghen
  • Pirenzepine HCl
  • Pirenzepine hydrochloride
  • Tabe
  • Ulcosan
  • UNII-10YM403FLS

Systematic Names

  • 5,11-Dihydro-11-((4-methylpiperazin-1-yl)acetyl)-6H-pyrido(2,3-b)(1,4)benzodiazepin-6-one dihydrochloride
  • 6H-Pyrido(2,3-b)(1,4)benzodiazepin-6-one, 5,11-dihydro-11-((4-methyl-1-piperazinyl)acetyl)-, dihydrochloride

Registry Numbers

CAS Registry Number

  • 29868-97-1

FDA UNII

  • 10YM403FLS

System Generated Number

  • 0029868971

Molecular Formulas

Molecular Formula

  • C19-H21-N5-O2.2Cl-H

Molecular Formula Fragments

  • C19-H21-N5-O2
  • Cl-H
  • COMPONENT

Structure Descriptors

InChI

1S/C19H21N5O2.2ClH/c1-22-9-11-23(12-10-22)13-17(25)24-16-7-3-2-5-14(16)19(26)21-15-6-4-8-20-18(15)24;;/h2-8H,9-13H2,1H3,(H,21,26);2*1H

InChIKey

FFNMBRCFFADNAO-UHFFFAOYSA-N

Smiles

CN1CCN(CC1)CC(=O)N2c3ccccc3C(=O)Nc4c2nccc4.Cl.Cl

Toxicity

Organism Test Type Route Reported Dose (Normalized Dose) Effect Source
dog LD50 intravenous 62500ug/kg (62.5mg/kg)   Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 19, Pg. 544, 1988.
dog LD50 oral > 3700mg/kg (3700mg/kg)   Drugs in Japan Vol. -, Pg. 900, 1990.
mouse LD50 intraperitoneal 412mg/kg (412mg/kg)   Polish Journal of Pharmacology and Pharmacy. Vol. 33, Pg. 615, 1981.
mouse LD50 intravenous 96mg/kg (96mg/kg)   Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 19, Pg. 735, 1988.
mouse LD50 oral 2600mg/kg (2600mg/kg) BEHAVIORAL: COMA

LUNGS, THORAX, OR RESPIRATION: DYSPNEA

BEHAVIORAL: ATAXIA
Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 11, Pg. 328, 1980.
mouse LD50 subcutaneous 2100mg/kg (2100mg/kg)   Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 19, Pg. 735, 1988.
rabbit LD50 oral 3gm/kg (3000mg/kg)   Oyo Yakuri. Pharmacometrics. Vol. 9, Pg. 377, 1975.
rat LD50 intraperitoneal 440mg/kg (440mg/kg)   Gekkan Yakuji. Pharmaceuticals Monthly. Vol. 23, Pg. 1999, 1981.
rat LD50 intravenous 92mg/kg (92mg/kg)   Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 19, Pg. 735, 1988.
rat LD50 oral 5gm/kg (5000mg/kg) BEHAVIORAL: ATAXIA

LUNGS, THORAX, OR RESPIRATION: DYSPNEA

BEHAVIORAL: COMA
Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 11, Pg. 328, 1980.
rat LD50 subcutaneous 3gm/kg (3000mg/kg)   Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 19, Pg. 735, 1988.